Showing Results for
- Academic Journals (15)
Search Results
- 15
Academic Journals
- 15
- Search Terms:
- 1From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: P. Parikh, T. Puri Management of lung cancer has undergone a dramatic transformation over the last few years. [sup][1] It can easily be said that non-small-cell lung cancer (NSCLC) is the poster boy of...
- 2From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: V. Noronha, V. Patil, B. Bhosale, A. Joshi, N. Purandare, K. Prabhash Context: Advanced esophageal cancer is aggressive with an expected median survival of 6-7 months. Combination chemotherapy regimens...
- 3From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: A. Choughule, V. Noronha, A. Joshi, S. Desai, N. Jambhekar, S. Utture, A. Thavamanni, K. Prabhash, A. Dutt Background: The Medical Oncology Department at Tata Memorial Hospital, the single largest tertiary...
- 4From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: A. Bhatt, R. Pai, G. Rebekah, G. Nehru, S. Dhananjayan, A. Samuel, A. Singh, A. Joel, A. Korula, R. Chacko Introduction: We performed retrospective analysis of 106 patients with lung cancer for which...
- 5From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: S. Desai, A. Shah, K. Prabhash, N. Jambhekar Background: An in-frame fusion protein between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic large cell kinase (ALK) genes is seen in some...
- 6From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedIndian Journal of Cancer January-March 2013; Vol 50; Issue 1 Title: Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference? Page 1; Authors: VM Patil,...
- 7From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: N. Andre, E. Pasquier Thirteen years ago, the simultaneous publications by teams of Judah Folkman and Bob Kerbel [sup][1],[2] reporting on the antiangiogenic effects of frequent administrations of low dose...
- 8From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: V. Noronha, V. Patil, A. Joshi, K. Prabhash Context: There are limited effective therapeutic options in the relapsed setting for non-small cell lung cancer (NSCLC) or in the first line for platinum-ineligible...
- 9From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: S. Banavali, N. Patil, V. Nirabhawane, B. Bhosale, S. Desai Cholangiocarcinoma (CCa) is relatively resistant to chemotherapy as well as radiation therapy, and complete resection is the main curative therapy...
- 10From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: H. Perroud, M. Rico, C. Alasino, S. Pezzotto, V. Rozados, O. Scharovsky Background: Metronomic chemotherapy (MCT) with cyclophosphamide (Cy) and celecoxib (Cel) has therapeutic efficacy and low toxicity...
- 11From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: N. Tandon, S. Banavali, H. Menon, S. Gujral, P. Kadam, A. Bakshi Acute myeloid leukemia (AML) in older adults differs biologically and clinically from that in younger patients and is characterized by adverse...
- 12From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: P. Pai, A. Vaidya, K. Prabhash, S. Banavali Context: Head and neck cancers in developing countries present with advanced disease, compounded by poor access to tertiary care centers. Aim: We evaluated oral...
- 13From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: V. Noronha, M. Krishna, V. Patil, A. Joshi, S. Banavali, K. Prabhash Cytotoxic antiproliferative chemotherapeutic agents are the mainstay of treatment in cancers. Chemotherapy is usually administered every...
- 14From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: J. Mehta Background: Lung cancer is the leading cause of cancer related mortality world-wide and amongst males in India. The discovery of tyrosine kinase inhibitors holds a ray of hope for a subset of lung...
- 15From: Indian Journal of Cancer. (Vol. 50, Issue 2) Peer-ReviewedByline: V. Veldore, R. Rao, S. Kakara, S. Pattanayak, R. Tejaswi, R. Sahoo, E. Venkataswamy, S. Prabhudesai, N. Krishnamoorthy, B. Tejaswini, D. Hazarika, S. Gangoli, S. Rahman, R. Naik, R. Diwakar, C. Satheesh, S....